anti-CD19 CAR-T cells(University of California) Due Diligenc

This anti-CD19 CAR-T cells(University of California) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 26 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Not disclosed

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether anti-CD19 CAR-T cells(University of California) can convert its Not disclosed profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	anti-CD19 CAR-T cells(University of California) (query alias: anti-CD19 CAR-T cells(University of California))
Modality / target	Not disclosed; Not disclosed; Not disclosed
Highest global status	Not disclosed
Originator	Not disclosed
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04545762	Phase 1	Recruiting	36	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Unmasking the Hidden Burden: Non-Icans Neurotoxicities after CAR-T Therapy — a Systematic Review

Phase 1/2; n=376; evaluation: Negative. Reported fields: AE = In CARTITUDE-1, a phase Ib/II trial of ciltacabtagene autoleucel (cilta-cel) in 97 patients with heavily pretreated multiple myeloma, six patients (6%) developed parkinsonism, including one treatment-related death due to progressive parkinsonism. In CARTITUDE-4, a phase III trial comparing cilta-cel to standard therapy in lenalidomide-refractory multiple myeloma, 1 of 176 patients in the cilta-cel arm developed movement and neurocognitive treatment-emergent adverse events (MNTs), while 16 (9%) experienced cranial nerve palsies and 5 (2.8%) developed peripheral neuropathy. In a retrospective cohort of 86 patients with relapsed or refractory ALL, NHL, or CLL receiving CD19-directed CAR-T therapy, Coredeiro et al. observed new neurologic findings in 9 patients (10%), totaling 11 events. Reported complications included cerebrovascular accidents, transient ischemic attack, Alzheimer-like dementia, and peripheral neuropathy. In a phase I study of GPRC5D-targeted CAR-T cells (MCARH109) by Mailankody et al., 2 of 17 patients (11.8%) developed grade 3 cerebellar dysfunction at 6.5 and 8.4 months post-infusion, manifesting as severe, delayed motor coordination deficits unrelated to ICANS. ; AE = In CARTITUDE-1, a phase Ib/II trial of ciltacabtagene autoleucel (cilta-cel) in 97 patients with heavily pretreated multiple myeloma, six patients (6%) developed parkinsonism, including one treatment-related death due to progressive parkinsonism. In CARTITUDE-4, a phase III trial comparing cilta-cel to standard therapy in lenalidomide-refractory multiple myeloma, 1 of 176 patients in the cilta-cel arm developed movement and neurocognitive treatment-emergent adverse events (MNTs), while 16 (9%) experienced cranial nerve palsies and 5 (2.8%) developed peripheral neuropathy. In a retrospective cohort of 86 patients with relapsed or refractory ALL, NHL, or CLL receiving CD19-directed CAR-T therapy, Coredeiro et al. observed new neurologic findings in 9 patients (10%), totaling 11 events. Reported complications included cerebrovascular accidents, transient ischemic attack, Alzheimer-like dementia, and peripheral neuropathy. In a phase I study of GPRC5D-targeted CAR-T cells (MCARH109) by Mailankody et al., 2 of 17 patients (11.8%) developed grade 3 cerebellar dysfunction at 6.5 and 8.4 months post-infusion, manifesting as severe, delayed motor coordination deficits unrelated to ICANS.

Outpatient Administration of Commercial antiCD19 and Antibcma Chimeric Antigen Receptor-Modified T-Cell (CAR-T) Therapies Using a Strategy of No Remote Monitoring and Early Cytokine Release Syndrome (CRS) Intervention

Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Adverse Event: CRS = CRS occurred in 35 (73%) patients; all grade 1-2. Hospitalization for CRS was prevented in 7 patients with OP Toci administration while 11 were admitted for persistent CRS despite OP Toci. ; Adverse Event: CRS = CRS occurred in 35 (73%) patients; all grade 1-2. Hospitalization for CRS was prevented in 7 patients with OP Toci administration while 11 were admitted for persistent CRS despite OP Toci.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

anti-CD19 CAR-T cells(University of California) addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Not disclosed—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
No matched asset transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION